Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, United States.
Department of Pharmaceutical Sciences, College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK 73117, United States; Optimum Therapeutics LLC, Carlsbad, CA 92008, United States.
J Control Release. 2018 Jan 28;270:101-113. doi: 10.1016/j.jconrel.2017.12.001. Epub 2017 Dec 22.
RNA Interference (RNAi) is a potentially useful tool to correct the detrimental effects of faulty genes; several RNAi are undergoing clinical evaluation in various diseases. The present study identified the relative contributions of three mechanisms by which polyanion drugs reduced the gene silencing activity of Lipoplex, a complex of small interfering RNA (siRNA) and cationic liposomes. The study used a siRNA against the chemoresistance gene survivin and two model polyanion drugs (suramin, heparin). Products of Lipoplex destabilization were separated, identified, and/or quantified using ultrafiltration, gel electrophoresis, and RT-qPCR (quantitative reverse transcription polymerase chain reaction). Cell binding and endocytosis of fluorescence-labeled Lipoplex and the amount of siRNA at its site of action RISC (RNA-induced silencing complex) were evaluated using endocytosis markers, confocal microscopy, quantitative image analysis, immunoprecipitation, and RT-qPCR. The results show suramin and heparin exerted multiple concentration-dependent effects. First, these agents altered several Lipoplex properties (i.e., reduced particle size, changed surface charge, modified composition of protein biocorona). Second, both caused Lipoplex destabilization to release double- and single-strand siRNA and/or smaller siRNA-lipid complexes with reduced siRNA cargo. Third, both prevented the cell surface binding and internalization of Lipoplex, diminished the siRNA concentration in RISC, and retarded the mRNA knockdown. Suramin and heparin yielded qualitatively and quantitatively different results. Analysis of the experimental results of suramin using quantitative pharmacology (QP) modeling indicated the major cause of gene silencing activity loss depended on drug concentration, changing from inhibition of endocytosis at lower concentration (accounting for 60% loss at ~9μM) to inhibition of cell surface binding and loss of siRNA cargo at higher concentrations (accounting for 64% and 27%, respectively, at 70μM). In summary, the present study demonstrates the complex and dynamic interactions between polyanions and Lipoplex, and the use of QP modeling to delineate the contributions of three mechanisms to the eventual loss of gene silencing activity.
RNA 干扰(RNAi)是一种纠正有缺陷基因有害影响的潜在有用工具;几种 RNAi 正在各种疾病中进行临床评估。本研究确定了三种机制的相对贡献,这些机制通过这些机制,多阴离子药物降低了小干扰 RNA(siRNA)和阳离子脂质体复合物 Lipoplex 的基因沉默活性。该研究使用了针对化疗耐药基因 survivin 的 siRNA 和两种模型多阴离子药物(苏拉明、肝素)。使用超滤、凝胶电泳和 RT-qPCR(定量逆转录聚合酶链反应)分离、鉴定和/或定量 Lipoplex 失稳产物。使用内吞作用标记物、共焦显微镜、定量图像分析、免疫沉淀和 RT-qPCR 评估荧光标记的 Lipoplex 的细胞结合和内吞作用以及其作用部位 RISC(RNA 诱导的沉默复合物)的 siRNA 量。结果表明苏拉明和肝素发挥了多种浓度依赖性作用。首先,这些试剂改变了 Lipoplex 的几种特性(即,减小粒径、改变表面电荷、改变蛋白生物被膜的组成)。其次,两者都导致 Lipoplex 不稳定,从而释放双链和单链 siRNA 和/或更小的 siRNA-脂质复合物,减少 siRNA 货物。第三,两者都阻止了 Lipoplex 的细胞表面结合和内化,减少了 RISC 中的 siRNA 浓度,并延迟了 mRNA 敲低。苏拉明和肝素产生了定性和定量不同的结果。使用定量药理学(QP)建模对苏拉明实验结果的分析表明,基因沉默活性丧失的主要原因取决于药物浓度,在较低浓度下(在约 9μM 时占 60%的损失)从抑制内吞作用变为抑制细胞表面结合和 siRNA 货物丢失在较高浓度下(分别占 64%和 27%,在 70μM 时)。总之,本研究表明多阴离子与 Lipoplex 之间存在复杂而动态的相互作用,并使用 QP 建模来描绘三种机制对最终基因沉默活性丧失的贡献。